Rhode Island Chronicle

Pancreatic Ductal Adenocarcinoma Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies FDA approvals, Route of Administration, and Developments

 Breaking News
  • No posts were found

Pancreatic Ductal Adenocarcinoma Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies FDA approvals, Route of Administration, and Developments

March 16
23:48 2023
Pancreatic Ductal Adenocarcinoma Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies FDA approvals, Route of Administration, and Developments
Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Pancreatic Ductal Adenocarcinoma pipeline constitutes 80+ key companies continuously working towards developing 80+ Pancreatic Ductal Adenocarcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Pancreatic Ductal Adenocarcinoma Overview

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive lethal malignancy due to the lack of early diagnosis and limited response to treatments. It is the most prevalent type of pancreatic neoplasm, and it is developed in the exocrine compartment and accounts for more than 90% of pancreatic cancer cases.

 

Pancreatic Ductal Adenocarcinoma Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pancreatic Ductal Adenocarcinoma Market.

 

The Pancreatic Ductal Adenocarcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Pancreatic Ductal Adenocarcinoma Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Pancreatic Ductal Adenocarcinoma treatment therapies with a considerable amount of success over the years. Pancreatic Ductal Adenocarcinoma Key players such as – Elicio Therapeutics, General Oncology, Inc., Revolution Medicines, Amplia Therapeutics, Lisata Therapeutics, Inc., Cardiff Oncology, Eucure Biopharma, Panbela Therapeutics, Inc., Jiangsu Alphamab Biopharmaceuticals, Novartis Pharmaceuticals, ZielBio, and others, are developing therapies for the Pancreatic Ductal Adenocarcinoma treatment 
  • Pancreatic Ductal Adenocarcinoma Emerging therapies such as – ELI-002, Melphalan, RMC-6236, ZB131, AMP 945, CEND-1, Onvansertib, YH003, SBP-101, KN046, NIS793, and others are expected to have a significant impact on the Pancreatic Ductal Adenocarcinoma market in the coming years.   
  • In July 2022, Cend Therapeutics, Inc. announced that The Lancet Gastroenterology and Hepatology published data from the Phase 1b study of CEND-1, Cend’s lead investigational drug, in combination with gemcitabine and nab-paclitaxel for the treatment of first-line, metastatic pancreatic ductal adenocarcinoma (“mPDAC”)
  • In July 2022, I-Mab announced that the first patient in China has been treated with TJ-CD4B (also known as ABL111), a novel Claudin 18.2 x 4-1BB bispecific antibody, in a Phase 1 international multi-center clinical trial (IMCT) for patients with solid tumors, including gastric cancer, gastroesophageal junction carcinoma, esophageal adenocarcinoma, and pancreatic ductal carcinoma
  • In January 2022, Jiangsu Alphamab Biopharmaceuticals initiated a multicenter, randomized, double-blind Phase III study to assess the efficacy and safety of KN046 combined with Gemcitabine and NabPaclitaxel versus placebo combined with Gemcitabine and Nab-Paclitaxel in first line Advanced Pancreatic Ductal Adenocarcinoma subjects (ENREACH-PDAC-01)
  • In November 2021, Alphamab Oncology announced that the IND application for phase III registration study (KN046-303) of the PD-L1/CTLA-4 bispecific antibody KN046 plus nab-paclitaxel/gemcitabine for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC) was approved by the Center for Drug Evaluation (CDE) of the NMPA

 

Route of Administration

Pancreatic Ductal Adenocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Intravenous
  • Subcutaneous

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Small molecule
  • Cell Therapy
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Pancreatic Ductal Adenocarcinoma Pipeline Therapeutics Assessment

  • Pancreatic Ductal Adenocarcinoma Assessment by Product Type
  • Pancreatic Ductal Adenocarcinoma By Stage and Product Type
  • Pancreatic Ductal Adenocarcinoma Assessment by Route of Administration
  • Pancreatic Ductal Adenocarcinoma By Stage and Route of Administration
  • Pancreatic Ductal Adenocarcinoma Assessment by Molecule Type
  • Pancreatic Ductal Adenocarcinoma by Stage and Molecule Type

 

DelveInsight’s Pancreatic Ductal Adenocarcinoma Report covers around 80+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Some of the key companies in the Pancreatic Ductal Adenocarcinoma Therapeutics Market include:

Key companies developing therapies for Pancreatic Ductal Adenocarcinoma are – Alligator Bioscience, Cardiff Oncology, Novartis, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Cantargia AB, Nelum Corp, GC Cell Corporation, OSE Immunotherapeutics, Eucure (Beijing) Biopharma Co., Ltd, Panbela Therapeutics, Inc., Onconic Therapeutics Inc., Elicio Therapeutics, Cend Therapeutics, Silenseed Ltd, Amplia Therapeutics Limited, Bristol-Myers Squibb, Revolution Medicines, Inc., Taiho Pharmaceutical, Genmab, Deciphera Pharmaceuticals LLC, NGM Biopharmaceuticals, Multitude Therapeutics, Seagen Inc., Tarveda Therapeutics, I-Mab Biopharma Co. Ltd., Incyte Corporation, ZielBio, Inc., DrugCendR Inc., Bayer, TriSalus Life Sciences, Jacobio Pharma, BioLineRx Ltd., Purple Biotech Ltd., Biomea Fusion, Inc., Phanes Therapeutics, Qualigen Therapeutics, and others.

 

Emerging Pancreatic Ductal Adenocarcinoma Drugs Under Different Phases of Clinical Development Include:

  • ELI-002: Elicio Therapeutics
  • Melphalan: General Oncology, Inc.
  • RMC-6236: Revolution Medicines
  • ZB131: ZielBio
  • Nadunolimab: Cantargia
  • AMP 945: Amplia Therapeutics
  • Zimberelimab: Arcus Biosciences
  • CEND-1: Lisata Therapeutics, Inc.
  • Onvansertib: Cardiff Oncology
  • YH003: Eucure Biopharma
  • SBP-101: Panbela Therapeutics, Inc.
  • KN046:  Jiangsu Alphamab Biopharmaceuticals
  • NIS793: Novartis Pharmaceuticals

 

Get a Free Sample PDF Report to know more about Pancreatic Ductal Adenocarcinoma Pipeline Therapeutic Assessment- 

https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight

 

Pancreatic Ductal Adenocarcinoma Pipeline Analysis:

The Pancreatic Ductal Adenocarcinoma pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Pancreatic Ductal Adenocarcinoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pancreatic Ductal Adenocarcinoma Treatment.
  • Pancreatic Ductal Adenocarcinoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Pancreatic Ductal Adenocarcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  •  Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pancreatic Ductal Adenocarcinoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Pancreatic Ductal Adenocarcinoma product details are provided in the report. Download the Pancreatic Ductal Adenocarcinoma pipeline report to learn more about the emerging Pancreatic Ductal Adenocarcinoma therapies

 

Pancreatic Ductal Adenocarcinoma Pipeline Market Drivers

  • Increasing pervasiveness of the disease
  • Increasing demand of targeted therapy

 

Pancreatic Ductal Adenocarcinoma Pipeline Market Barriers

  • Lack of early diagnostic markers
  • Complicated and multifactorial nature of disease
  • Diverse genetics and rapid metastasis

 

Scope of Pancreatic Ductal Adenocarcinoma Pipeline Drug Insight    

  • Coverage: Global
  • Key Pancreatic Ductal Adenocarcinoma Companies: , and others
  • Key Pancreatic Ductal Adenocarcinoma Therapies: ELI-002, Melphalan, RMC-6236, ZB131, AMP 945, CEND-1, Onvansertib, YH003, SBP-101, KN046, NIS793, and others
  • Pancreatic Ductal Adenocarcinoma Therapeutic Assessment: Pancreatic Ductal Adenocarcinoma current marketed and Pancreatic Ductal Adenocarcinoma emerging therapies
  • Pancreatic Ductal Adenocarcinoma Market Dynamics: Pancreatic Ductal Adenocarcinoma market drivers and Pancreatic Ductal Adenocarcinoma market barriers 

 

Request for Sample PDF Report for Pancreatic Ductal Adenocarcinoma Pipeline Assessment and clinical trials

 

Table of Contents

1

Pancreatic Ductal Adenocarcinoma Report Introduction

2

Pancreatic Ductal Adenocarcinoma Executive Summary

3

Pancreatic Ductal Adenocarcinoma Overview

4

Pancreatic Ductal Adenocarcinoma- Analytical Perspective In-depth Commercial Assessment

5

Pancreatic Ductal Adenocarcinoma Pipeline Therapeutics

6

Pancreatic Ductal Adenocarcinoma Late Stage Products (Phase II/III)

7

Pancreatic Ductal Adenocarcinoma Mid Stage Products (Phase II)

8

Pancreatic Ductal Adenocarcinoma Early Stage Products (Phase I)

9

Pancreatic Ductal Adenocarcinoma Preclinical Stage Products

10

Pancreatic Ductal Adenocarcinoma Therapeutics Assessment

11

Pancreatic Ductal Adenocarcinoma Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Pancreatic Ductal Adenocarcinoma Key Companies

14

Pancreatic Ductal Adenocarcinoma Key Products

15

Pancreatic Ductal Adenocarcinoma Unmet Needs

16 

Pancreatic Ductal Adenocarcinoma Market Drivers and Barriers

17

Pancreatic Ductal Adenocarcinoma Future Perspectives and Conclusion

18

Pancreatic Ductal Adenocarcinoma Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

Download Sample PDF Report to know more about Pancreatic Ductal Adenocarcinoma drugs and therapies

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services